Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Herbert I. Hurwitz; Louis Fehrenbacher; William Novotny; Thomas H. Cartwright; John D. Hainsworth; W. Heim; Jordan Berlin; Ari David Baron; S. Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert W. Ross; Fairooz F. Kabbinavar

doi:10.1056/nejmoa032691

Abstract

The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.

Keywords

MedicineIrinotecanBevacizumabFluorouracilColorectal cancerOncologyInternal medicineChemotherapyCancer

MeSH Terms

AntibodiesMonoclonalAntibodiesMonoclonalHumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCamptothecinColorectal NeoplasmsDisease-Free SurvivalFemaleFluorouracilHumansIrinotecanLeucovorinMaleMiddle AgedNeoplasm MetastasisQuality of LifeSurvival Analysis

Affiliated Institutions

Related Publications

Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study

Thierry Conroy , B Paillot , Éric François +10 more

Purpose To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA). Pati...

2005 Journal of Clinical Oncology 238 citations

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn , Shukui Qin , Masafumi Ikeda +18 more

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...

2020 New England Journal of Medicine 6464 citations

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

Michael J. Overman , Sara Lonardi , Ka Yeung Mark Wong +17 more

Purpose Nivolumab provides clinical benefit (objective response rate [ORR], 31%; 95% CI, 20.8 to 42.9; disease control rate, 69%; 12-month overall survival [OS], 73%) in previou...

2018 Journal of Clinical Oncology 1962 citations

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

Hedy L. Kindler , Donna Niedzwiecki , Donna Hollis +12 more

Purpose The combination of gemcitabine plus bevacizumab produced a 21% response rate and a median survival of 8.8 months in a multicenter phase II trial in patients with metasta...

2010 Journal of Clinical Oncology 834 citations

Therapeutic Synergy Between Irinotecan and 5-Fluorouracil against Human Tumor Xenografts

Rami G. Azrak , Shousong Cao , Harry K. Slocum +7 more

Abstract Purpose: Although the combination of irinotecan and 5-Fluorouracil is clinically active, it is associated with significant toxicity and resistance. Studies were carried...

2004 Clinical Cancer Research 100 citations

Publication Info

Year: 2004
Type: article
Volume: 350
Issue: 23
Pages: 2335-2342
Citations: 10885
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

10885

OpenAlex

318

Influential

8420

CrossRef

Cite This

APA Style

                            
                                
                                    Herbert I. Hurwitz, 
                                
                                    Louis Fehrenbacher, 
                                
                                    William Novotny
                                
                                et al.
                            
                            (2004). 
                            Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. 
                            New England Journal of Medicine
                            , 350
                            (23)
                            , 2335-2342.
                            https://doi.org/10.1056/nejmoa032691
                        

Identifiers

DOI: 10.1056/nejmoa032691
PMID: 15175435

Data Quality

Data completeness: 86%